Key Anti-Aging Drugs Market Players:
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- L’Oréal S.A. (Active Cosmetics Division)
- Johnson & Johnson
- Pfizer Inc.
- Bayer AG
- GlaxoSmithKline (GSK)
- Novartis AG
- Amorepacific Corporation
- Rejuvenate Bio
- Eisai Co., Ltd.
- Dr. Reddy's Laboratories
- Calico Life Sciences (Alphabet Inc.)
- Evolus, Inc.
- Medytox, Inc.
- CSL Limited
- Hims & Hers Health, Inc.
- Lupin Limited
- Biocon Biologics
- Forest Biosciences
- Chugai Pharmaceutical Co., Ltd. (Roche Subsidiary)
The anti-aging drugs market is very competitive and is driven by the key pharmaceutical, cosmeceutical, and biotech players. Firms such as AbbVie, Novartis, and GSK are actively investing in cellular rejuvenation, NAD+ pathway modulation, and senolytics. Strategic partnerships, including Pfizer’s collaboration with biotech startups and investments by Alphabet’s Calico, further fuel the R&D innovation. Companies in Asia are increasing in both modern and traditional bioactive compounds. Companies in India are aiming for biosimilar-related aging therapies to broaden access with cost effective therapies.
Here is a list of key players operating in the anti-aging drugs market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of anti-aging drugs is assessed at USD 55.88 billion.
The global anti-aging drugs market size crossed USD 52.27 billion in 2025 and is likely to register a CAGR of over 6.9%, exceeding USD 101.87 billion revenue by 2035.
North America is dominating the anti-aging drugs market and is poised to hold a share of 40% at a CAGR of 13.8% by 2035
Key players in the market include L'Oréal SA, Merz Pharma GmbH & Co., Novartis AG, BioTime Inc., ARK Skincare, Elysium Health Inc., Estée Lauder Inc., DermaFix, Bayer Pharma AG, La Roche-Posay.
